Novartis To Pull Valturna From U.S. Market As FDA Warns Of Risks With Aliskiren Meds
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warns that use of aliskiren-containing blood pressure drugs with ACE inhibitors or angiotensin receptor blockers may increase risk of kidney impairment, hypotension and hyperkalemia; Novartis to continue to sell four other aliskiren products.